Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis serogroups A, C, y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom

Pediatric Infectious Disease Journal

Volumn 32, Issue 7, 2013, Pages 768-776

  Blanchard Rohner, Geraldine ^a,b   Snape, Matthew D ^a,c   Kelly, Dominic F ^a,c   O'Connor, Daniel ^a   John, Tessa ^a,c   Kibwana, Elizabeth ^a   Parks, Hannah ^a   Ford, Karen ^a   Dull, Peter M ^d   Pollard, Andrew J ^a,c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^d Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

Human; Maternal antibodies; Neisseria meningitidis

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; DIPHTHERIA TOXOID CRM197; IMMUNOGLOBULIN G ANTIBODY; MATERNAL ANTIBODY; MENINGOCOCCUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MEMORY CELL; NEISSERIA MENINGITIDIS; NONHUMAN; OPEN STUDY; PLACENTAL TRANSFER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROPREVALENCE; SERUM BACTERICIDAL ACTIVITY; UNITED KINGDOM; VACCINATION;

ANTIBODIES, BACTERIAL; B-LYMPHOCYTES; FEMALE; GREAT BRITAIN; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOLOGIC MEMORY; INFANT; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS; PLACENTA; PREGNANCY; SEROEPIDEMIOLOGIC STUDIES; VACCINATION;

EID: 84883241853     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318292f425     Document Type: Article

References (40)

1. Health Protection Agency. Meningococcal disease-Epidemiological data. Available at: http://www.hpa.org.uk/Topics/InfectiousDiseases/ InfectionsAZ/MeningococcalDisease/EpidemiologicalData/.
2. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307-1326.
3. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine. 2007;25:6296-6304.
4. Gonik B, Puder KS, Gonik N, et al. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol. 2005;13:59-61.
5. Takizawa T, Anderson CL, Robinson JM. A novel Fc gamma R-defined, IgG-containing organelle in placental endothelium. J Immunol. 2005;175: 2331-2339.
6. Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365-3369.
7. de Voer RM, van der Klis FR, Nooitgedagt JE, et al. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis. 2009;49:58-64.
8. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine. 2003;21:3406-3412.
9. Siegrist CA, Barrios C, Martinez X, et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol. 1998;28:4138-4148.
10. Tiru M, Hallander HO, Gustafsson L, et al. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine. 2000;18:2295-2306.
11. Holmlund E, Nohynek H, Quiambao B, et al. Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination. Vaccine. 2011;29:4565-4575.
12. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299:173-184.
13. Gheesling LL, Carlone GM, Pais LB, et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol. 1994;32:1475-1482.
14. Griffiss JM. Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model. Rev Infect Dis. 1982;4:159-172.
15. Kelly DF, Snape MD, Perrett KP, et al. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology. 2009;127:134-143.
16. Blanchard-Rohner G, Snape MD, Kelly DF, et al. The magnitude of the antibody and memory B cell responses during priming with a proteinpolysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol. 2008;180:2165-2173.
17. Kelly DF, Snape M, Clutterbuck EC, et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen specific memory B cells. Blood. 2006;180:2642-2647.
18. Granoff DM, Maslanka SE, Carlone GM, et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol. 1998;5:479-485.
19. Amir J, Louie L, Granoff DM. Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine. 2005;23:977-983.
20. Sánchez S, Troncoso G, Criado MT, et al. Interspecific neisserial high molecular weight proteins able to induce natural immunity responses are strongly correlated with in vitro bactericidal activity. Vaccine. 2002;20:2964-2971.
21. Troncoso G, Sánchez S, Moreda M, et al. Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species. FEMS Immunol Med Microbiol. 2000;27:103-109.
22. Filice GA, Hayes PS, Counts GW, et al. Risk of group A meningococcal disease: bacterial interference and cross-reactive bacteria among mucosal flora. J Clin Microbiol. 1985;22:152-156.
23. Robbins JB, Myerowitz L, Whisnant JK, et al. Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun. 1972;6:651-656.
24. Trotter CL, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol. 2008;15:1694-1698.
25. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50:1601-1610.
26. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9:213-220.
27. Department of Health. Joint Committee on Vaccination and Immunisation MotmoWOL. In: Joint Committee on Vaccination and Immunisation, Minute of the meeting on Wednesday 3 October 2012. London; 2012.
28. Blanchard-Rohner G, Pollard AJ. Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy. Expert Rev Vaccines. 2011;10:673-684.
29. Mulholland K, Suara RO, Siber G, et al. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. JAMA. 1996;275:1182-1188.
30. Steinhoff MC, Omer SB, Roy E, et al. Influenza immunization in pregnancy-antibody responses in mothers and infants. N Engl J Med. 2010;362:1644-1646.
31. Siegrist CA, Lambert PH. Maternal immunity and infant responses to immunization: factors influencing infant responses. Dev Biol Stand. 1998;95:133-139.
32. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine. 2003;21(suppl 2):S35-S37.
33. Leuridan E, Hens N, Hutse V, et al. Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine. 2011;29:2222-2226.
34. Leuridan E, Hens N, Hutse V, et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ. 2010;340:c1626.
35. Ochola R, Sande C, Fegan G, et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One. 2009;4:e8088.
36. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics. 1995;96(3 Pt 2): 580-584.
37. Nohynek H, Gustafsson L, Capeding MR, et al. Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. Pediatr Infect Dis J. 1999;18:25-30.
38. Bell F, Heath P, MacLennan J, et al. Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule. Eur J Pediatr. 1999;158:329-336.
39. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J. 2005;24(suppl 5):S62-S65.
40. Nguyen TV, Yuan L, Azevedo MS, et al. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen. Clin Vaccine Immunol. 2006;13: 475-485.